Low-Dose Aspirin Demonstrates ‘Huge Effect’ in Stopping Colorectal Cancer Recurrence, Research Confirms

An everyday intake of this common painkiller can substantially lower the likelihood of certain colorectal cancers coming back after surgical removal, as per a large-scale trial into the beneficial properties of the common medication.

Scandinavian investigators discovered that individuals who consumed a low everyday amount of the drug after receiving cancer surgery were 50% unlikely to suffer a cancerous return over the next several years versus those who were given a dummy pill.

The study included participants whose tumors had certain genetic mutations that caused them susceptible to its anti-cancer effects. Around four in ten of bowel cancer individuals possess similar alterations.

“I believe this may alter treatment protocols,” commented a lead researcher. “In cases involving these alterations, the chance of the cancer recurring was lowered by over a significant margin. It is a major benefit.”

Almost 2 million patients are found to have colorectal cancer annually around the world, with more than thousands of instances in the UK. Many receive tumour surgery, but regardless of advances in chemotherapy, radiotherapy and operations, the malignancy can come back if malignant cells are remaining.

Incidence of intestinal cancer are rising across the globe in individuals younger than 50, and while the causes are not fully understood, experts theorize that unhealthy diets, being overweight, a absence of physical activity and chemicals created by intestinal microbes are involved.

Earlier trials have shown that aspirin can help stop colorectal cancer in people who are at increased risk due to inherited syndromes such as a genetic condition. However, it was unclear whether the drug decreased the likelihood of cancer returning after surgery.

Investigators recruited over thousands of participants who had received colorectal tumor resection at hospitals across several countries. DNA analysis on nearly 3,000 of the patients identified a significant number, or more than a third, had mutations in genetic material that are part of a cellular pathway known as a specific pathway, which is involved in the disease.

The individuals with the genetic traits were divided to receive either a low dose of medication daily or a inactive pill for three years after surgery. Those using the active drug were more than half less likely to see the malignancy return than those taking the control group, the research confirmed.

The medication appears to guard against malignancy by dampening immune response, interfering with the specific mechanism, and reducing the behavior of blood platelets, which can surround tumour cells and thereby hide them from the body’s natural protection.

Researchers emphasized the need to run genetic tests on every bowel cancers so that people who might profit from aspirin could be offered the medication. “This is a widely available drug that is highly inexpensive,” commented.

Aspirin has been available for longer than a century, but taking the treatment over extended periods still poses potential side effects. In the trial, several participants had “severe reactions” possibly linked to the treatment, such as hypersensitivity, stomach bleeding and intracranial bleeding. Four participants died across the two groups of the study, with one death likely caused by the drug.

A research director stated: “Stopping cancer diagnoses preserves life, and identifying new ways to achieve this is crucial to the mission to overcome malignancy. There is increasing evidence that in certain individuals of people, low-dose this treatment can give protection from colorectal cancer.”

“We need larger, well-designed trials to confirm which individuals would see the greatest advantage from consuming aspirin to help them live longer, improved lives, free from the anxiety of the disease.”